-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
LumiraDx (NASDAQ:LMDX) Receives New Coverage From Analysts at The Goldman Sachs Group
LumiraDx (NASDAQ:LMDX) Receives New Coverage From Analysts at The Goldman Sachs Group
The Goldman Sachs Group started coverage on shares of LumiraDx (NASDAQ:LMDX – Get Rating) in a research note released on Monday morning, The Fly reports. The firm issued a neutral rating on the stock.
Separately, Raymond James decreased their price target on shares of LumiraDx from $4.00 to $3.50 and set an outperform rating on the stock in a research report on Friday, November 11th.
Get LumiraDx alerts:LumiraDx Stock Performance
NASDAQ LMDX opened at $0.96 on Monday. The company has a debt-to-equity ratio of 20.12, a current ratio of 2.91 and a quick ratio of 1.63. The firm has a market capitalization of $43.43 million, a price-to-earnings ratio of -0.68 and a beta of 1.05. The company's fifty day moving average is $1.09 and its two-hundred day moving average is $1.66. LumiraDx has a 52-week low of $0.77 and a 52-week high of $10.42.
Institutional Trading of LumiraDx
Several institutional investors have recently made changes to their positions in LMDX. Bill & Melinda Gates Foundation acquired a new stake in shares of LumiraDx during the 3rd quarter valued at about $14,600,000. Senvest Management LLC lifted its holdings in LumiraDx by 297.0% during the 3rd quarter. Senvest Management LLC now owns 10,737,651 shares of the company's stock valued at $10,952,000 after purchasing an additional 8,032,616 shares during the last quarter. Balyasny Asset Management LLC lifted its holdings in LumiraDx by 36,072.9% during the 3rd quarter. Balyasny Asset Management LLC now owns 3,771,385 shares of the company's stock valued at $3,847,000 after purchasing an additional 3,760,959 shares during the last quarter. Pictet Asset Management SA bought a new position in LumiraDx during the 3rd quarter valued at about $1,659,000. Finally, Colony Group LLC bought a new position in LumiraDx during the 2nd quarter valued at about $787,000.LumiraDx Company Profile
(Get Rating)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
See Also
- Get a free copy of the StockNews.com research report on LumiraDx (LMDX)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.
The Goldman Sachs Group started coverage on shares of LumiraDx (NASDAQ:LMDX – Get Rating) in a research note released on Monday morning, The Fly reports. The firm issued a neutral rating on the stock.
据The Fly报道，高盛在周一上午发布的一份研究报告中开始对LumiraDx(纳斯达克代码：lmdx-Get Rating)的股票进行报道。该公司对该股的评级为中性。
Separately, Raymond James decreased their price target on shares of LumiraDx from $4.00 to $3.50 and set an outperform rating on the stock in a research report on Friday, November 11th.
另外，Raymond James在11月11日星期五的一份研究报告中将LumiraDx的目标价从4.00美元下调至3.50美元，并对该股设定了表现优于大盘的评级。
LumiraDx Stock Performance
LumiraDx股票表现
NASDAQ LMDX opened at $0.96 on Monday. The company has a debt-to-equity ratio of 20.12, a current ratio of 2.91 and a quick ratio of 1.63. The firm has a market capitalization of $43.43 million, a price-to-earnings ratio of -0.68 and a beta of 1.05. The company's fifty day moving average is $1.09 and its two-hundred day moving average is $1.66. LumiraDx has a 52-week low of $0.77 and a 52-week high of $10.42.
纳斯达克LMDX周一开盘价为0.96美元。该公司的债务权益比为20.12，流动比率为2.91，速动比率为1.63。该公司市值为4,343万美元，市盈率为-0.68倍，贝塔系数为1.05。该公司的50日移动均线切入位在1.09美元，200日移动均线切入位在1.66美元。LumiraDx的52周低点为0.77美元，52周高点为10.42美元。
Institutional Trading of LumiraDx
LumiraDx的机构交易
LumiraDx Company Profile
LumiraDx公司简介
(Get Rating)
(获取评级)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
LumiraDx有限公司是一家医疗诊断公司。该公司专注于通过向医疗保健提供者提供关键诊断信息来转变基于社区的医疗保健。它制造和销售一种诊断平台，该平台支持各种测试，在护理点具有实验室可比的性能。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on LumiraDx (LMDX)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- 免费获取StockNews.com在LumiraDx(LMDX)上的研究报告
- 如果马斯克退出Twitter，特斯拉的股价会上涨吗？
- 2023年值得关注的5个下跌但不是下跌的股票
- Chewy能否在2023年获得两位数的增长？
- 礼来公司预计将实现持久增长，尽管面临眼前的挑战
- Madrigal制药公司的股票在一天内上涨了200%，原因如下
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.
接收LumiraDx日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对LumiraDx和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧